Chronic GVHD (cGVHD) poses a significant risk for hematopoietic stem cell transplantation (HSCT) patients. Preclinical development of new therapeutic modalities has been hindered by models with pathological findings that may not simulate the development of human cGVHD. Previously we have demonstrated that cGVHD induced by allogeneic HSCT following a conditioning regimen of cyclophosphamide and total body radiation results in pulmonary dysfunction and airway obliteration leading to bronchiolitis obliterans (BO), pathognomonic for cGVHD. We now report cGVHD manifestations in a wide-spectrum of target organs, including those with mucosal surfaces. Fibrosis was demonstrated in the lung and liver, associated with CD4 + T-cells and B220 + B-cell infiltration and alloantibody deposition. Robust germinal center (GC) reactions were present at the time of cGVHD disease initiation. Blockade of GC formation using a lymphotoxin-beta receptor -immunoglobulin (LTβR-Ig) fusion protein suppressed cGVHD and BO. Donor bone marrow obtained from mice incapable of secreting IgG alloantibody resulted in less BO and cGVHD. We conclude that cGVHD is caused in part by alloantibody secretion, which is associated with fibrosis and cGVHD manifestations including BO and that LTβR-Ig treatment could be beneficial for cGVHD prevention and therapy.
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Introduction
Chronic GVHD (cGVHD) is a significant complication of allogeneic hematopoietic stem cell transplantation (HSCT) 1 . Progress in developing interventional strategies to counter cGVHD has been hampered by variable onset and pathological manifestations of cGVHD, now better defined by the NIH consensus conference 2 , and a dearth of robust preclinical venues that closely mimic conditions in which cGVHD is generated and manifested 3 .
Although the exact causes of cGVHD are unknown, higher antibody levels have been associated with autoimmunity and implicated in cGVHD 4, 5 . Studies of newly diagnosed patients with extensive cGVHD, had elevated soluble BAFF levels and anti-ds-DNA antibodies 6, 7 . Increased soluble BAFF in cGVHD was associated with higher circulating levels of pre-germinal center (GC) B-cells and post-GC plasmablasts 8 . B-cells from cGVHD patients were hyper-responsive to TLR-9 signaling and have upregulated CD86 levels 9 ; suggesting an important participatory role for B-cells in establishing cGVHD, emphasizing the need for further investigation into the immunological role of B-cells in cGVHD pathogenesis.
Existing murine cGVHD models simulate one or more of the pathological manifestations such as increased serum antibodies (typically anti-DNA antibodies), scleroderma and fibosis of skin and liver, and the less common immune complex deposition in kidneys and glomerulonephritis [10] [11] [12] . The type of multi-organ involvement and alloantibodies seen in cGVHD patients often has not been well-represented in these preclinical models.
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From Moreover, some models do not involve conditioning regimens, whereas others relay upon radiation alone. Previously, our laboratory has studied pulmonary dysfunction and chronic GVHD (cGVHD) target organ pathology in animals conditioned with high dose cyclophosphamide (Cy) and lethal total body irradiation (TBI) rescued with allogeneic bone marrow (BM) and splenocytes 13 . The functional, physiological, and pathological assays demonstrated that Cy and TBI conditioned recipients of low numbers of allogeneic T-cells developed bronchiolitis obliterans (BO) 14, 15 18 and cGVHD [19] [20] [21] [22] . Aggregate analysis of 6 trials of steroid-refractory cGVHD showed overall response rates of 29-36% for oral, hepatic, gastrointestinal and lung cGVHD, and 60% for cutaneous cGVHD 23 .
Additional prevention and treatment strategies clearly are needed. We focused on GC . LTβR-Ig is a novel fusion protein that binds circulating lymphotoxin and inhibits LT-LTβR signaling 24 . We show that LTβR-Ig treatment of transplanted animals susceptible to establishment of cGVHD and BO showed improved lung function along with lower tissue-specific antibody levels in the sera and fibrosis of the lung and liver.
LTβR-Ig represents a potential new therapy for cGVHD prevention and treatment. ) and B6.129S2-Igh-6tm1Cgn/J on a C57Bl/6 background (referred to as μMT mice) were purchased from Jackson Laboratories. BALB/c (m+s)IgMxJhD Tg mice 25 were bred at the University of Minnesota animal facility. Mice were housed in a specific pathogen-free facility and used with the approval of the University of Minnesota institutional animal care.
BMT
B10.BR recipients were conditioned with Cy on days -3 and -2 (120mg/kg/day i.p.). On day-1, recipients received TBI by x-ray (7.5Gy). Donor bone marrow (BM) was T-cell depleted with anti-Thy1.2 mAb followed by rabbit complement. T-cells were purified from lymph nodes by incubation with phycoerythrin-labeled anti-CD19 (eBioscience), followed by anti-PE beads and depletion with magnetic column (Miltenyi-Biotec 
Pulmonary function tests (PFTs)
PFTs were performed as described 13 . Anesthetized mice were weighed and lung function assessed by whole body plethysmography using the Flexivent system (Scireq) and analyzed using the Flexivent software version5.1.
Frozen tissue preparation
All organs harvested were embedded in Optimal Cutting Temperature compound (OCT), snap frozen in liquid nitrogen, and stored in -80°. Lungs were inflated by infusing 1 ml of OCT: PBS (3:1) intratracheally prior to harvest.
Histology and trichrome staining
6 μm cryosections were fixed for 5 minutes in acetone and stained with hematoxylin and eosin to determine pathology and with the Masson's trichrome staining kit (Sigma) for detection of collagen deposition. Histopathology scores were assigned as described 26 .
Collagen deposition was quantified on trichrome stained sections as a ratio of area of blue staining to area of total staining using the Adobe Photoshop CS3 analysis tool.
Immunohistochemistry
Acetone fixed 6 μm cryosections were immunoperoxidase stained using biotinylated mAbs for CD4, CD8, and B220 (BDPharmingen) 26 
GC detection
Fixed 6µm spleen cryosections were stained with rat-anti-mouse-VCAM1 followed by goat-anti-rat-Cy3, IgM-FITC and biotinylated-PNA (Vector Laboratories) followed by Streptavidin-Cy5. Confocal images obtained as above.
Statistics
Survival data were analyzed by life- PFTs showed an increase in airway resistance, correlating to lung constriction, increased elastance and decreased compliance signifying increased stiffness or rigidity of the lungs.
These data simulate BO manifestations in cGVHD patients 16 . A decrease in pulmonary function and increased pathology was noticed as early as 28 days post transplantation were significantly higher in the cGVHD group compared with BM controls ( Figure 2B ).
In the liver, peri-vasculature infiltration was observed surrounding the bile duct and extending into the parenchyma (Figure 2A ), resulting in a significant increase in the pathology score in the cGVHD vs. the BM control animals ( Figure 2B ). Mice with higher pathology scores also had necrotic foci of cells in the parenchyma proper.
Since patients with cGVHD may also have oral mucosal involvement, histopathology of the tongue and salivary glands was examined. Areas of infiltration, inflammation and abscess formation were observed on the tongue near the taste receptors ( Figure 2A ). The pathology score was significantly higher, albeit modest in magnitude, in the cGVHD group compared with the BM only controls ( Figure 2B ). Salivary glands displayed perivascular infiltration; however this infiltration was also seen in the BM controls suggesting changes resulting from the conditioning ( Figure 2A ).
The thymus, known to be involved in human cGVHD 27 , displayed necrotic foci, and destruction of stromal matrix, resulting in a significantly higher cGVHD pathology score.
The spleen had abnormal architecture similar to the thymus, albeit only modest differences were seen in the pathology score. The colon displayed moderate pathology in the cGVHD cohorts, but not as extensive or invasive as in aGVHD models. The ileum displayed mild pathology seen in both the cGVHD and the BM group, suggesting the role of pre-transplant conditioning.
cGVHD has been characterized as a fibroproliferative disease, therefore collagen levels were quantified by trichrome staining. The lung and liver (Figures 2C and D) both displayed a significant increase in collagen deposition around bronchioles and blood vessels. The organization of the collagen surrounding the bronchioles and blood vessels is highlighted ( Figure 2C ) demonstrating the increase of collagen localized to specific structures and not uniformly distributed throughout the lungs and liver. Fibrosis patterns in tongue and salivary glands were somewhat more variable between individual mice within a group and trichrome staining was not significantly increased as compared with the BM controls (data not shown).
Overall, Cy/TBI conditioning followed by transfer of a number of low splenocyte infusion reproduced the pathology of cGVHD. It was distinguished from aGVHD by the absence of significant weight loss early and overall mild losses later after transplant, BO, involvement of the oral mucosa, and fibrosis in cGVHD target organs. Whereas pathology and fibrosis in the lung has been observed previously 13 ; documented reports of pathology in the other organs have not been evaluated.
CD4 + T-cell and B-cell infiltration and alloantibody deposition in cGVHD target organs.
We sought to determine the potential associated etiopathogenic mechanisms associated with cGVHD. We focused on the lung and liver as the two more severely affected cGVHD organs denoted by obstructive PFTs and the presence of fibrosis. CD4 + T-cell infiltration was observed in peribronchiolar areas in the cGVHD group but not in BM only controls ( Figure 3A ). The liver displayed substantial infiltration in the perivascular areas ( Figure 3A ) and for some recipients, into the parenchyma (not shown). Due to the degree of lung inflation influencing the distribution of cells, percentage of lymphocytes are quantified in the lung versus total number like with the liver. The number CD4 + T-cells in the lung ( Figure 3B ) and the liver ( Figure 3C ) was significantly higher in the cGVHD group compared with the BM only control, consistent with other models in which CD4 + T-cells could be found in cGVHD organs 10 . There was only minimal infiltration of CD8 + T-cells in both groups (data not shown). B220 + B-cell infiltration in the lung and liver ( Figure 3D ) was seen in a pattern similar to CD4 + T-cells. A significant increase in total B220 + B-cells in the lung and liver was seen in the cGVHD group compared with the BM controls ( Figures 3E, F, respectively) . Salivary glands and the tongue had only minimal B220 + B-cell infiltration (data not shown). Taken together, the pathology in the lung and liver is associated with CD4 + T-cell and B-cell infiltration.
We hypothesized that B-cell secreted antibodies might play a role in cGVHD pathology and determined whether antibody deposition could be observed in cGVHD organs on day 60 post-transplantation. The lung and liver had deposits of mouse Ig within surrounding areas of infiltration and pathologic effects ( Figure 4A ). There were peribronchiolar deposits and perivascular deposits in both organs. Quantification of Ig deposition in the lung and liver ( Figure 4B ) revealed higher levels in the cGVHD group than the BM control. The predominant Ig types were IgG2c in the lung and liver (Supplemental Figure   3 and data not shown).
To determine if circulating anti-host, tissue-reactive antibodies were present, sera from Consistent with the finding that disruption of GC formation would diminish BO and cGVHD generation, day 60 PFTs in the cGVHD cohorts indicated that LTβR-Ig but not control protein treated recipients displayed lower resistance and elastance and higher compliance ( Figure 7D ). Both liver and pulmonary fibrosis was reduced by LTβR-Ig ( Figure 7E ). Thus, LTβR-Ig treatment given post-transplantation ameliorates the development of BO and cGVHD. The pathological scores shows that BM+spleen+MOPC21 mean lung scores are ~5 fold higher than BM+spleen+LTβRig (Supplemental Figure 7) , although these differences did not reach statistical significance.
For the liver, recipients given BM+spleen+MOPC21 had a reduction in mean scores compared to BM+spleen and no Ig control, thereby making it difficult to assess the extent to which LTβR-Ig was superior to MOPC21, although we can state that BM+spleen had higher scores than BM alone which were compared to BM+spleen+LTβR-Ig, indicating that the LTβR-Ig did indeed reduce the severity of pathological injury. These data are supportive of our findings that LTβR-Ig reduces cGVHD as measured by pulmonary These results suggest that B-cells via their antibody secretory capability contribute to pulmonary dysfunction and liver pathology in animals that suffer from chronic GVHD after transplantation, and interventional strategies that inhibit pathways involved in B-cell function and antibody secretion maybe useful in the prevention or treatment of cGVHD.
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Discussion
We report that Cy/TBI conditioned allogeneic recipients given low splenocyte or T-cell doses developed multi-organ system pathology with fibrosis and BO pathognomonic of cGVHD. cGVHD development was associated with IgG2c deposition in the lung and liver and IgG2b in the liver, which was abrogated if the donor BM was deficient in mature B-cells or incapable of producing anti-host reactive IgG. Robust GC formation was seen in mice with cGVHD. By disrupting GC formation using LTβR-Ig, BO was reduced. Together, these data indicate that GC formation and IgG secretion by donor BM-derived mature B-cells are necessary for cGVHD pathology.
By using Cy, which exacerbates the TBI-induced glutathione redox reactions in the lung 30 . In studies using mice and monkeys it has been shown that rituximab treatment is more successful in removal of B cells from the blood compared to the spleen and lymph nodes 38, 39 . GC B-cells display lower susceptibility to rituximab-mediated clearance, probably because they reside in a non optimal environment for antibody based depletion 18 . Our observation that GC B-cells are critical to the development of cGVHD suggests that agents that are more effective at disrupting the GC might be more clinically useful. We are unaware of the use of rituximab in a systemic fashion to determine the effects on BO in cGVHD patients. Such studies would require patients with the same duration of onset and severity of BO. To our knowledge, the relative number and 
